Progress of lymphoid-specific tyrosine phosphatase inhibitors / 药学学报
Acta Pharmaceutica Sinica
;
(12): 699-705, 2017.
Artículo
en Chino
| WPRIM
| ID: wpr-779647
ABSTRACT
Lymphoid-specific tyrosine phosphatase (LYP) is a phosphatase that is encoded by protein tyrosine phosphatase non-receptor type 22 and is mainly distributed in lymphoid. In psychological condition, LYP inhibits T-cell receptor (TCR) signaling in association with C-terminal kinase (CSK). While in pathological condition, mutant LYP dissociates with CSK, which augments the inhibition of TCR signaling and leads to autoimmune diseases. Consequently, LYP is now considered as a new target of type I diabetes, rheumatic arthritis and Graves disease and some other autoimmune disorders. This review mainly focuses on the development of LYP inhibitors in their structures and activities.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Acta Pharmaceutica Sinica
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS